{"id":170585,"date":"2025-11-09T00:11:27","date_gmt":"2025-11-09T00:11:27","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/170585\/"},"modified":"2025-11-09T00:11:27","modified_gmt":"2025-11-09T00:11:27","slug":"consumer-healthcare-mega-merger-kimberly-clark-to-acquire-tylenol-maker-kenvue-in-48-7-billion-cash-and-stock-deal-1-9-billion-cost-savings-targeted-post-merger","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/170585\/","title":{"rendered":"Consumer healthcare mega merger: Kimberly-Clark to acquire Tylenol maker Kenvue in $48.7 billion cash and stock deal; $1.9 billion cost savings targeted post-merger"},"content":{"rendered":"<p> <img src=\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/11\/1762647087_787_-.jpg\" alt=\"Consumer healthcare mega merger: Kimberly-Clark to acquire Tylenol maker Kenvue in $48.7 billion cash and stock deal; $1.9 billion cost savings targeted post-merger\" title=\"Photo credit- AP\" decoding=\"async\" fetchpriority=\"high\"\/> Kimberly-Clark is set to acquire Tylenol maker Kenvue in a cash-and-stock transaction valued at approximately $48.7 billion, creating one of the world\u2019s largest consumer health goods companies, AP reported.Under the terms of the agreement, Kenvue shareholders will receive $3.50 per share in cash and 0.14625 Kimberly-Clark shares for each Kenvue share held at closing. Based on Kimberly-Clark\u2019s closing share price on Friday, the deal values Kenvue stock at $21.01 per share.Following the merger, Kimberly-Clark shareholders will own around 54% of the combined entity, while Kenvue shareholders will hold about 46%. The companies said the merger is expected to generate annual net revenues of approximately $32 billion in 2025. They also identified an estimated $1.9 billion in cost savings to be realised within the first three years after the deal closes.\u201cWith a shared commitment to developing science and technology to provide extraordinary care, we will serve billions of consumers across every stage of life,\u201d said Kimberly-Clark Chairman and CEO Mike Hsu in a statement.Hsu will lead the merged company as chairman and CEO, while three members of Kenvue\u2019s board will join Kimberly-Clark\u2019s board upon closing. The combined company will retain Kimberly-Clark\u2019s headquarters in Irving, Texas, and maintain a significant presence at Kenvue\u2019s existing locations.The acquisition is expected to close in the second half of next year, pending approval from shareholders of both companies.In early trading, Kimberly-Clark shares dropped more than 15% before the market open, while Kenvue\u2019s stock surged over 20%.<\/p>\n","protected":false},"excerpt":{"rendered":"Kimberly-Clark is set to acquire Tylenol maker Kenvue in a cash-and-stock transaction valued at approximately $48.7 billion, creating&hellip;\n","protected":false},"author":2,"featured_media":170586,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[97528,97529,18,135,475,474,19,17,97527,97531,94694,97526,97530],"class_list":{"0":"post-170585","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-consumer-healthcare-mega-merger","9":"tag-cost-savings-merger","10":"tag-eire","11":"tag-health","12":"tag-health-care","13":"tag-healthcare","14":"tag-ie","15":"tag-ireland","16":"tag-kenvue-merger","17":"tag-kenvue-shareholders","18":"tag-kimberly-clark","19":"tag-kimberly-clark-acquisition","20":"tag-tylenol-maker"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/115516846116213383","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/170585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=170585"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/170585\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/170586"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=170585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=170585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=170585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}